We are looking to implement appropriate safeguards for storage, dispensing, and administration of Myxredlin (insulin infusion). We are concerned with packaging and the risk of mix-ups with other bags which look similar--ISMP has already reported an actual error where insulin infusion run instead of cefazolin.

Can you share your practices for safeguards around following:

Can you share with me if you are using continuous pulse oximetry or capnography to monitor for opioid sedation in patients at greater risk, specifically asking for those areas outside of the critical care space.

Also, have you implemented the Michigan Opioid Safety Score (MOSS) or any other proactive screening tools to assess patients at greater risk for opioid sedation? Can you share which tool you are using?

Hello,
The FDA recently released a Medwatch alert on serious breathing problems for patients taking gabapentin or pregabalin and other CNS depressants. Also there's been more articles regarding misuse of gabapentin and baclofen (https://www.tandfonline.com/doi/pdf/10.1080/15563650.2019.1687902?needAc...), especially with the initiatives to reduce opioid use and increase use of other pain medications.

I’d like to know which of the narcotics and controlled medications are allowed to be in the ward and the ER? Is there a specific list or a policy?
Thank you

Wondering if anyone has strategies for handling situations where NIOSH table 1 oral medications need to be given via routes other than Oral, i.e. NG/OG/JT. Seems like USP 800 does not allow manipulation of a tablet or capsule outside of a CACI/BSC/powder hood?

hello,

I need updated list of medication do not tube, and if any one have information about transferring sterile preparation via pneumatic tube.

thank you,

hello,

I need updated list of medication do not tube, and if any one have information about transferring sterile preparation via pneumatic tube.

thank you,

Hello,
Looking to review/revise our DKA policy. Would anyone be willing to share your protocols/policies?

Thank you,
Renu Bajwa, Pharm.D.
Medication Safety Coordinator
Community Memorial Health System
Ventura, CA 93003

We have been asked to evaluate the possibility of preparing autologous serum eyedrops (SED). There are numerous issues ranging from regulatory (in NY SED use is considered a blood derivative "re-infusion"), preparation standards - eg USP <797>, to infection control considerations.
If you do prepare SED in your pharmacy would you be willing to share your procedures?

If you allow use of SED in inpatients (either patient "own" or institutionally prepared), how do you handle specifics of dispensing, storage and infectious disease exposure risk to staff and environment?

Happy New Year everyone! Curious if anyone has made changes in the EHR across the board (all drugs or a specific subset of drugs) to reduce the likelihood the nurse accidentally interprets the product concentration as the dose to administer. Would love to understand what changes people have made.